Pharma Exec Warns EU Transparency Push Could Delay Drug Applications

Clinical Trials Advisor
If EU regulators and pharma cannot agree on how to handle publication of clinical trial data, drugmakers may delay filing applications in Europe to preserve exclusivity, a Pfizer official says.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00